<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327612</url>
  </required_header>
  <id_info>
    <org_study_id>20101116</org_study_id>
    <nct_id>NCT01327612</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of Conatumumab and AMG 479</brief_title>
  <official_title>A Phase 2 Open Label Extension Study of Conatumumab and AMG 479</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to allow continued treatment with conatumumab and/or AMG 479,
      with or without chemotherapy to subjects without disease progression whose previous studies
      were closed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2011</start_date>
  <completion_date type="Anticipated">July 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety profile, including adverse events and serious adverse events, of conatumumab, with or without co-therapy, or AMG 479.</measure>
    <time_frame>Two to three years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Carcinoid</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Locally Advanced</condition>
  <condition>Lymphoma</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Combination Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment: Conatumumab Q2W or Q3W + ongoing chemotherapy or ganitumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy treatment: Conatumumab Q2W or Q3W; or AMG 479 Q3W or Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6</intervention_name>
    <description>Oxaliplatin: 100mg/m2, IV in 500mL of D5W over 120 minutes on Day 1 Leucovorin: 400mg/m2, IV diluted in D5W over 120 minutes (concurrently with oxaliplatin) on Day 1 Fluorouracil: 400 mg/m2, IV bolus, after leucovorin, on Day 1 Fluorouracil: 2400mg/m2, CIV over 46 hours (single dose) start on Day 1 Cycle frequency: repeat every 14 days until disease progression or unacceptable toxicity</description>
    <arm_group_label>Combination Treatment</arm_group_label>
    <other_name>Oxaliplatin-Leucovorin-Fluorouracil chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conatumumab</intervention_name>
    <description>Conatumumab is an investigational, fully human monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR-5.</description>
    <arm_group_label>Combination Treatment</arm_group_label>
    <other_name>AMG 655</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conatumumab</intervention_name>
    <description>Conatumumab is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR5.</description>
    <arm_group_label>Monotherapy Treatment</arm_group_label>
    <other_name>AMG 655</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ganitumab</intervention_name>
    <description>Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.</description>
    <arm_group_label>Combination Treatment</arm_group_label>
    <other_name>AMG 479</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Recombinant humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF); angiogenesis inhibitor.</description>
    <arm_group_label>Combination Treatment</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ganitumab</intervention_name>
    <description>Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.</description>
    <arm_group_label>Monotherapy Treatment</arm_group_label>
    <other_name>AMG 479</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be enrolled in this study, subjects must be currently enrolled in a prior
             Amgen-sponsored conatumumab or AMG 479 study and are eligible according to the parent
             study to receive their next dose of conatumumab (with or without co-therapy), or AMG
             479 alone.

        Subjects must have their eligibility assessed for this study and be enrolled within 30 days
        of their last treatment on the parent protocol

        Exclusion Criteria:

          -  Discontinued from a conatumumab study due to an adverse event considered by the
             investigator to be related to conatumumab treatment, including intolerance to
             conatumumab

          -  Subjects determined to have disease progression during their participation in the
             parent Amgen study

          -  Woman or man with partner of childbearing potential not consenting to use adequate
             contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus
             condom), or abstinence during the course of the study and for 6 months after the last
             dose of protocol-specified therapy administration

          -  Subject is pregnant or breast feeding, or planning to become pregnant within 6 months
             after the last dose of protocol-specified therapy administration

          -  Male subject with a pregnant partner who is not willing to use a condom during
             treatment and for an additional 6 months after the last dose of protocol-specified
             therapy administration

          -  Subject has previously entered this study

          -  Subject will not be available for protocol required study visits, to the best of the
             subject and investigator's knowledge

          -  Subject has any kind of disorder that, in the opinion of the investigator, may
             compromise the ability of the subject to give written informed consent and/or to
             comply with all required study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0957</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 655</keyword>
  <keyword>AMG 479</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Tumor Necrosis Factor</keyword>
  <keyword>Insulin-like Growth Factor</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Modified FOLFOX6</keyword>
  <keyword>mFOLFOX6</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Trail Receptor</keyword>
  <keyword>ganitumab</keyword>
  <keyword>conatumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

